Transmedics Group Inc [TMDX] stock prices are up 1.94% to $70.33 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TMDX shares have gain 4.84% over the last week, with a monthly amount drifted -6.25%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on December 17, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $75 from $116. Previously, Needham downgraded its rating to Hold on November 22, 2024. On October 29, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $125 on the stock. Needham reiterated its Buy rating and decreased its price target to $109 on October 29, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $200 as its price target on September 24, 2024. Needham started tracking with a Buy rating for this stock on August 21, 2024, and assigned it a price target of $208. In a note dated June 06, 2024, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $161 on this stock.
The stock price of Transmedics Group Inc [TMDX] has been fluctuating between $55.00 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $110.6 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $70.33 at the most recent close of the market. An investor can expect a potential return of 57.26% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
The Transmedics Group Inc [NASDAQ:TMDX] reported sales of 441.54M for trailing twelve months, representing a surge of 49.83%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.18 and Total Capital is 0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 68.79 points at the first support level, and at 67.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 72.09, and for the 2nd resistance point, it is at 73.85.
Ratios To Look Out For
It’s worth pointing out that Transmedics Group Inc [NASDAQ:TMDX]’s Current Ratio is 8.30. On the other hand, the Quick Ratio is 7.52, and the Cash Ratio is 5.62. Considering the valuation of this stock, the price to sales ratio is 5.36, the price to book ratio is 10.34 and price to earnings (TTM) ratio is 69.62.
Transactions by insiders
Recent insider trading involved Khayal Tamer I, Chief Commercial Officer, that happened on Mar 03 ’25 when 2407.0 shares were sold. Officer, Gordon Stephen completed a deal on Mar 04 ’25 to buy 5942.0 shares. Meanwhile, Chief Commercial Officer Khayal Tamer I sold 1083.0 shares on Jan 07 ’25.
